Balsalazide Disodium vs Sulfasalazine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Aminosalicylate

Balsalazide Disodium

First FDA approval: 2007-12-28

Aminosalicylate

Sulfasalazine

Brand: Azulfidine

First FDA approval: 1950-06-20

Lowest NADACAcquisition cost floor across all NDCs

$0.372Per unit

$0.197Per unit

Average NADACAcross all dosage forms and strengths

$0.372Up to $0.372

$0.209Up to $0.278

Generic manufacturersActive ANDA holders — FDA Orange Book

55 total ANDAs filed

45 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$27.8MFull year

$29.2MFull year

Part D claims (CY24)Total fills, all strengths

160K44K beneficiaries

877K273K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$174Per claim, all NDCs

$33Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

Yes4 manufacturers